{
  "pmcid": "11109034",
  "sha256": "a46529ecf572bdf01678d2779c746a5091fa5864d74c7cd69b0dcdd378bdac33",
  "timestamp_utc": "2025-11-09T23:12:43.338453+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.165103761348899,
    "reading_ease": 26.105701469952464,
    "word_count": 257
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Oral PDE-5 Inhibitors in Children with VSD and Pulmonary Hypertension"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Conducted as a prospective, randomised, double-blinded, single-centre trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "51 children with VSD and PH were enrolled"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to receive either sildenafil or tadalafil (n=34) or placebo (n=17)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to assess the impact of oral phosphodiesterase type 5 (PDE-5) inhibitors"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in right ventricle systolic pressure (RVSP) and mean pulmonary artery pressure (mPAP) postoperatively and at follow-up"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed"
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included outcome assessors, patients, and clinicians"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "51 children with VSD and PH were enrolled"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "No significant difference was observed in RVSP improvement between the PDE-5 inhibitor group and the placebo group postoperatively (p=0.255) and at follow-up (p=0.259)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Two deaths occurred in the PDE-5 group: one due to brady/asystole and another due to subarachnoid hemorrhage"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: IRB approval number: 10/2022 PDEI 11-2"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}